COST-EFFECTIVENESS ANALYSIS OF ADJUVANTED RSVPREF3 OA VACCINE IN ADULTS AGED =75 YEARS AND THE COMORBID POPULATION AGED 60-74 YEARS IN SWITZERLAND
Author(s)
Julian Ortner, MSc1, Laura Guggisberg, MSc1, Eleftherios Zarkadoulas, FHAS, CERA, MBA2.
1GSK, Baar, Switzerland, 2GSK, Wavre, Belgium.
1GSK, Baar, Switzerland, 2GSK, Wavre, Belgium.
OBJECTIVES: To estimate the incremental cost-effectiveness of adjuvanted respiratory syncytial virus (RSV) prefusion F protein (RSVPreF3) older adult (OA) vaccination compared with no vaccination, expressed as cost per quality-adjusted life-year (QALY) gained, in the general population aged ≥75 years and the comorbid population aged 60-74 years in Switzerland.
METHODS: A static multicohort Markov model was localised to the Swiss context and run from a healthcare payer perspective. The two target populations reflected the current national Swiss vaccination recommendation: the general population aged ≥75 years and the comorbid population aged 60-74 years, and compared a single dose of adjuvanted RSVPreF3 OA with no vaccination. A 1-month cycle length and a 5-year time horizon were adopted, with 30% vaccine coverage in the base case. Local epidemiological and healthcare resource use data were used, supplemented by systematic literature reviews and relevant data from other countries where necessary. Costs and outcomes were discounted at 3% annually. The incremental cost-effectiveness ratio (ICER) was calculated per QALY gained. Deterministic and probabilistic sensitivity analyses were conducted to assess the robustness of the results.
RESULTS: A single dose of adjuvanted RSVPreF3 OA vaccination was cost-effective versus no vaccination (willingness-to-pay threshold CHF 50,000/QALY): ICERs were CHF 8,225/QALY in adults aged ≥75 Years and CHF 13,779/QALY in the comorbid population aged 60-74 years. Over 5 years, vaccination prevented an estimated 10,509 outpatient visits, 2,265 hospitalisations and 656 deaths in the ≥75-year population, as well as 7,800 outpatient visits, 1,074 hospitalisations and 134 deaths in the 60-74-year comorbid population.
CONCLUSIONS: Vaccinating older adults with adjuvanted RSVPreF3 is a cost-effective strategy in both recommended Swiss target populations, preventing RSV-lower respiratory tract disease events, acute respiratory infections, hospitalisations and deaths over a 5-year horizon.
Funding: GSK.
METHODS: A static multicohort Markov model was localised to the Swiss context and run from a healthcare payer perspective. The two target populations reflected the current national Swiss vaccination recommendation: the general population aged ≥75 years and the comorbid population aged 60-74 years, and compared a single dose of adjuvanted RSVPreF3 OA with no vaccination. A 1-month cycle length and a 5-year time horizon were adopted, with 30% vaccine coverage in the base case. Local epidemiological and healthcare resource use data were used, supplemented by systematic literature reviews and relevant data from other countries where necessary. Costs and outcomes were discounted at 3% annually. The incremental cost-effectiveness ratio (ICER) was calculated per QALY gained. Deterministic and probabilistic sensitivity analyses were conducted to assess the robustness of the results.
RESULTS: A single dose of adjuvanted RSVPreF3 OA vaccination was cost-effective versus no vaccination (willingness-to-pay threshold CHF 50,000/QALY): ICERs were CHF 8,225/QALY in adults aged ≥75 Years and CHF 13,779/QALY in the comorbid population aged 60-74 years. Over 5 years, vaccination prevented an estimated 10,509 outpatient visits, 2,265 hospitalisations and 656 deaths in the ≥75-year population, as well as 7,800 outpatient visits, 1,074 hospitalisations and 134 deaths in the 60-74-year comorbid population.
CONCLUSIONS: Vaccinating older adults with adjuvanted RSVPreF3 is a cost-effective strategy in both recommended Swiss target populations, preventing RSV-lower respiratory tract disease events, acute respiratory infections, hospitalisations and deaths over a 5-year horizon.
Funding: GSK.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE136
Topic
Economic Evaluation, Health Policy & Regulatory, Health Technology Assessment
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines